SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales is pegged at Rs. 559.63 millions for the September 2022 quarter. The mentioned figure indicates a decline of about -69.54% as against Rs. 1837.12 millions during the year-ago period.A radical decline of -84.83% was reported in the net profit of the company for the quarter ended September 2022 to Rs. 90.48  millions from Rs. 596.59 millions.A decline of 163.26 millions was observed in the OP in the quarter ended September 2022 from 835.37 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 559.63 1837.12 -69.54 1261.82 3039.03 -58.48 4561.32 2615.03 74.43
Other Income 7.52 1.17 542.74 11.29 10.72 5.32 35.12 15.88 121.16
PBIDT 163.26 835.37 -80.46 347.26 1320.29 -73.70 1752.36 308.47 468.08
Interest 11.83 7.11 66.39 24.02 13.90 72.81 29.17 26.12 11.68
PBDT 151.43 828.26 -81.72 323.24 1306.39 -75.26 1723.19 282.35 510.30
Depreciation 38.27 26.45 44.69 69.58 47.06 47.85 106.44 64.36 65.38
PBT 113.16 801.81 -85.89 253.66 1259.33 -79.86 1616.75 217.99 641.66
TAX 22.68 205.22 -88.95 57.68 319.22 -81.93 416.29 63.84 552.08
Deferred Tax -3.09 2.23 -238.57 -3.09 2.23 -238.57 2.75 1.62 69.75
PAT 90.48 596.59 -84.83 195.98 940.11 -79.15 1200.46 154.15 678.76
Equity 103.76 103.76 0.00 103.76 103.76 0.00 103.76 103.76 0.00
PBIDTM(%) 29.17 45.47 -35.84 27.52 43.44 -36.65 38.42 11.80 225.68

Kwality Pharma Share Price

1581.45 -13.40 (-0.84%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×